For pharmaceutical manufacturers, speed-to-market is among the most valuable project outcomes.
Whether expanding biologics capacity, bringing GLP-1 production online or investing in advanced therapies, organizations are under pressure to deliver facilities faster while maintaining cost certainty and regulatory compliance.
Supply chains remain volatile, specialist resources are constrained and investment decisions face greater scrutiny than ever before.
In this environment, the biggest threat to project success is not technical execution. It is the inability to identify and respond to emerging risks early enough. Delayed decisions, late equipment deliveries, validation bottlenecks and limited visibility across a siloed patchwork of schedules can accumulate until delivery drifts off course.
By the time the impact becomes visible, recovery options are often limited and expensive. The organizations consistently delivering successful outcomes are taking a different approach.
They are treating risk intelligence as a strategic project delivery capability, using data to surface threats sooner, strengthen decisions and maintain momentum through delivery milestones spread across key schedule merge hotspots.
The traditional view of project controls is heavily focused on cost. However, across life sciences projects, some of the greatest financial exposure is created by program delay. Understanding the causes of delay and their potential cost implications is therefore becoming just as important as managing project expenditure itself. Linesight experience across Good Manufacturing Practice (GMP) programs indicates that extension and prolongation costs can account for a significant share of total escalation, making time-related exposure one of the biggest drivers of overall project outcomes.
Every week lost during delivery creates knock-on effects. Site costs accumulate. Specialist resources remain engaged longer than planned. Validation programs extend. Commercial benefits are delayed. In a sector where new manufacturing capacity can support critical therapies and significant revenue generation, delayed delivery carries consequences that extend beyond construction costs. This is why leading organizations focus on maintaining schedule-critical dates, not just controlling individual budget lines.
Small issues, major consequences - a practical example
One of the biggest challenges in life sciences delivery is that seemingly minor issues can create disproportionate program impacts. For example, on a recent major €1bn+ biologics facility, a supply chain issue (late mechanical piping delivery) was identified to be on the critical path following a schedule risk review by Linesight. By developing a risk model from the activity schedule, we could use the schedule risk model to map key piping completion delays to the merge hotspots on the Commissioning, Qualification and Validation (CQV) completion pathway. We could show a potential delay of +88 days and +27% cost variance to the Engineering Run Start milestone. For these types of pharma projects in a peak construction phase, with monthly prolongation cost of between €5-10m and significant CQV internal staffing costs, the visibility of the potential cost risk gave the project the data to help mobilize resources for immediate mitigation actions on the supply chain risk.
To summarize, projects teams are very good at identifying risks but often lack the required insight to translate how those risks interact across the wider program and the subsequent cost escalation that could materialize if the risks impact.
Where the greatest project risks are emerging
Drawing on Linesight’s experience across GMP program several recurring delivery themes are clear. Equipment supply chains continue to represent one of the largest sources of exposure. HVAC and air handling systems have contributed up to 57% of critical path schedule sensitivity in certain projects. Process piping has been associated with up to 33% of cost variance and up to 47% of schedule sensitivity. Chromatography skids, single-use assemblies and specialized manufacturing equipment also frequently emerge as major schedule drivers. Yet the most significant constraints are not always technical.
Decision-making speed has become a critical differentiator. Linesight 's experience indicates that delays of just two to four weeks in resolving key decisions can generate six to ten weeks of program delay because dependent activities are forced to wait.
Validation resources represent another growing constraint. Across analyzed portfolios, shortages of specialist CQV expertise contributed between 10% and 25% of schedule prolongation risk. These findings reinforce a broader point that project performance increasingly depends on organizational agility as much as engineering execution.
potential delay to the Engineering Run Start milestone from late mechanical piping delivery.
potential cost variance to the Engineering Run Start milestone linked to the same supply chain risk.
potential prolongation cost during peak construction on projects of this type.
From hindsight to foresight
The most successful organizations are moving away from traditional approaches that focus on reporting what has happened. Instead, they are investing in the ability to understand what is likely to happen next.
Quantitative Risk Analysis (QRA) allows project teams to model a wide range of cost and schedule outcomes, identify the issues with the greatest potential impact and test mitigation strategies before committing resources. The goal is not to produce more reports. The goal is to improve the quality and timing of decisions. By understanding where exposure exists and what drives it, project teams can focus effort on the interventions most likely to improve outcomes. They can allocate contingency more effectively, justify acceleration measures and strengthen delivery plans. This changes the conversation from reacting to issues after they occur to preventing them before they develop.
A major European biologics expansion program demonstrates what this approach can achieve. The €440m project initially appeared to be progressing towards its target. However, quantitative analysis revealed a different reality. The mid construction QRA indicated that the most likely completion date had drifted approximately six months beyond the program target, while potential costs now exceeded €470m. More than half of the exposure was linked to schedule-driven impacts.
Rather than waiting for those risks to materialize, the project team used the analysis to guide delivery strategy. Through multiple iterations of risk assessment, mitigation planning and program optimization, key exposures were reduced, schedule recovery measures were implemented and contingency was deployed strategically where it would create the greatest value.
The result was the recovery of approximately six months of schedule and delivery within the approved budget, with a final cost of €438.6m. The lesson is not that risk can be eliminated. It is that exposure becomes far easier to manage when it is visible early enough to influence decisions.
Building more predictable projects
Life sciences organizations are investing billions to expand capacity, accelerate innovation and strengthen supply chains. In that environment, delivery certainty is becoming just as important as the facilities themselves.
As projects become larger and more complex, certainty is emerging as a competitive advantage. The organizations achieving the strongest outcomes are not avoiding risk altogether. They are developing better visibility into it. They understand where vulnerabilities exist, how they affect program objectives and what actions deliver the greatest return.
This approach requires more than periodic reviews or static risk registers. It depends on continuous risk visibility, iterative integrated cost and schedule forecasting, data-driven governance and timely decision support with clear authorization thresholds and flexibility at the project level. When embedded effectively, these capabilities create a compounding benefit. Teams can address risks before they accumulate and keep projects aligned to commercial, regulatory and patient outcomes.
Organizations that can see emerging threats sooner and act with confidence will be better positioned to control costs, accelerate delivery and bring new therapies to market faster. For life sciences organizations, delivery certainty is now a commercial, regulatory and patient-care priority.